Sophie Kitzmueller

Salzburg, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa-associated advanced/metastatic cutaneous squamous cell carcinoma.

Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa-associated advanced/metastatic cutaneous squamous cell carcinoma.

Journal: The British journal of dermatology
Published: December 23, 2024

Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma.

Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma.

Journal: Journal for immunotherapy of cancer
Published: September 24, 2021

Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa.

Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa.

Journal: JCI insight
Published: June 01, 2021

Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa.

Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa.

Journal: Orphanet journal of rare diseases
Published: May 26, 2020

Profiling trial burden and patients' attitudes to improve clinical research in epidermolysis bullosa.

Profiling trial burden and patients' attitudes to improve clinical research in epidermolysis bullosa.

Journal: Orphanet journal of rare diseases
Published: February 14, 2020

Cutting Edge: Tissue Antigen Expression Levels Fine-Tune T Cell Differentiation Decisions In Vivo.

Cutting Edge: Tissue Antigen Expression Levels Fine-Tune T Cell Differentiation Decisions In Vivo.

Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: September 24, 2019

An ex vivo RNA trans-splicing strategy to correct human generalized severe epidermolysis bullosa simplex.

An ex vivo RNA trans-splicing strategy to correct human generalized severe epidermolysis bullosa simplex.

Journal: The British journal of dermatology
Published: August 05, 2018

Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial.

Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial.

Journal: Journal of the American Academy of Dermatology
Published: August 30, 2017

A Gene Gun-mediated Nonviral RNA trans-splicing Strategy for Col7a1 Repair.

A Gene Gun-mediated Nonviral RNA trans-splicing Strategy for Col7a1 Repair.

Journal: Molecular therapy. Nucleic acids
Published: September 28, 2015

Transgenic mouse technology in skin biology: generation of complete or tissue-specific knockout mice.

Transgenic mouse technology in skin biology: generation of complete or tissue-specific knockout mice.

Journal: The Journal of investigative dermatology
Published: December 20, 2013

Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study.

Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study.

Journal: Orphanet journal of rare diseases
Published: March 04, 2013

Transcutaneous immunotherapy via laser-generated micropores efficiently alleviates allergic asthma in Phl p 5-sensitized mice.

Transcutaneous immunotherapy via laser-generated micropores efficiently alleviates allergic asthma in Phl p 5-sensitized mice.

Journal: Allergy
Published: July 14, 2012
Showing 1-12 of 13

Last Updated: 09/26/2026